AlloVir discontinues all three Phase 3 posoleucel trials after DSMB futility analyses

Kalaris Therapeutics, Inc.

Three Phase 3 trials for prevention, hemorrhagic cystitis, and adenovirus stopped after separate DSMBs deemed each unlikely to meet primary endpoints.
No safety concerns observed; discontinuation based on pre-planned futility analyses.
Company to prioritize capital preservation; held $213.3M cash and equivalents as of Sep 30, 2023.
AlloVir will review strategic alternatives including merger, sale, or licensing of assets.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.